Compare
908 Devices Inc. vs Harvard Bioscience Inc vs Bionano Genomics, Inc. vs Precipio, Inc.
| Latest fiscal year | 908 Devices Inc. MASS | Harvard Bioscience Inc HBIO | Bionano Genomics, Inc. BNGO | Precipio, Inc. PRPO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $56.20M | $86.55M | $28.51M | $24.05M |
| Revenue growth (YoY) | +17.7% | -8.1% | -7.4% | +29.8% |
| Gross margin | 50.6% | 57.7% | 46.3% (computed) | 44.5% |
| Operating margin | -70.1% | -56.1% | -116.9% | -5.0% |
| Net margin | 34.7% | -65.5% | -92.6% | -1.5% |
| Net income | $19.49M | -$56.70M | -$26.39M | -$363.0K |
| EPS (Diluted) | $0.54 | -$1.28 | -$4.85 | -$0.23 |
| Operating cash flow | -$23.69M | $6.73M | -$16.34M | $685.0K |
| Free cash flow | -$24.64M | $5.47M | n/a | $359.0K |
| Cash & equivalents | $70.52M | $8.61M | $2.99M | $2.65M |
| Total assets | $190.07M | $80.07M | $73.58M | $21.32M |
| Total liabilities | $46.37M | $66.34M | $29.16M | $6.76M |
| Shareholders' equity | $143.70M | $13.73M | $44.42M | $14.56M |
| Return on year-end equity | 13.6% | -412.8% | -59.4% | -2.5% |
| Shares outstanding | 36.32M | 44.72M | 10.74M | 1.78M |
Revenue, most recent five fiscal years
| Fiscal year | 908 Devices Inc. | Harvard Bioscience Inc | Bionano Genomics, Inc. | Precipio, Inc. |
|---|---|---|---|---|
| Latest | $56.20M Ended 2025-12-31 | $86.55M Ended 2025-12-31 | $28.51M Ended 2025-12-31 | $24.05M Ended 2025-12-31 |
| 1 year earlier | $47.75M Ended 2024-12-31 | $94.14M Ended 2024-12-31 | $30.78M Ended 2024-12-31 | $18.53M Ended 2024-12-31 |
| 2 years earlier | $50.23M Ended 2023-12-31 | $112.25M Ended 2023-12-31 | $36.12M Ended 2023-12-31 | $15.20M Ended 2023-12-31 |
| 3 years earlier | $46.85M Ended 2022-12-31 | $113.33M Ended 2022-12-31 | $27.80M Ended 2022-12-31 | $9.41M Ended 2022-12-31 |
| 4 years earlier | $42.21M Ended 2021-12-31 | $118.90M Ended 2021-12-31 | $17.98M Ended 2021-12-31 | $8.85M Ended 2021-12-31 |